Johnson & Johnnson is warning doctors not to prescribe Doxil to new patients with ovarian cancer, multiple myeloma or AIDS-related Kaposi’s sarcoma due to a supply shortage.
Janssen, a unit of Johnson & Johnnson, sent a letter to doctors in the US on Tuesday saying that a contract manufacturer is experiencing production delays, reports the Wall Street Journal.
The firm’s New Jersey office said that it hopes to replenish supplies in late August.
Doxil is a formulation of the chemotherapy doxorubicin that shields the active ingredient inside a rubbery coating, which helps it evade the body’s immune system and circulate longer in the blood, giving it more time to attack cancer cells.
The news follows announcements by US hospitals that they were facing severe drug shortages earlier this month.
It was reported that in the last six months 82% of 802 hospitals were forced to delay treatment and three out of four hospitals reported rationing or implementing restrictions for drugs that are in short supply.